The patient voice: measuring what matters in lower-risk myelodysplastic syndromes treated with imetelstat

Puntos clave

• To assess the patient voice and understand which outcomes are most significant in lower-risk myelodysplastic syndromes treated with imetelstat.
• Evaluated patient-reported outcomes related to treatment.
• Used standardized questionnaires to quantify relevant symptoms and well-being.
• Analyzed data on treatment effects from patient perspectives.
• Identified key outcomes that patients consider important in their treatment journey.
• Found a discrepancy between clinical results and patient-reported outcomes, indicating areas for improvement.
• Emphasized the necessity of incorporating patient insights in treatment evaluations.